PHARMADRUG INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.03 CAD | 0.00% |
|
0.00% | -45.45% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2022 | - | Sales 2023 | - | Capitalization | 4.81M 6.57M |
|---|---|---|---|---|---|
| Net income 2022 | -8M -10.93M | Net income 2023 | -13M -17.77M | EV / Sales 2022 | - |
| Net Debt 2022 | 1.09M 1.49M | Net Debt 2023 | 1.34M 1.84M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-0.59
x | P/E ratio 2023 |
-0.24
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 99.12% |
More Fundamentals
* Assessed data
More news
More press releases
| Current month | +20.00% | ||
| 1 month | -25.00% | ||
| 3 months | -14.29% | ||
| 6 months | -45.45% | ||
| Current year | -45.45% |
1 week
0.02
0.03
1 month
0.020.04
Current year
0.020.08
1 year
0.020.08
3 years
0.020.63
5 years
0.021.61
10 years
0.024.55
| Managers | Title | Age | Since |
|---|---|---|---|
Robert Steen
CEO | Chief Executive Officer | - | 23-09-05 |
Paul van Slyke
CTO | Chief Tech/Sci/R&D Officer | - | 21-05-12 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Paul McClory
BRD | Director/Board Member | 80 | 16-12-19 |
Al Quong
BRD | Director/Board Member | 58 | 19-05-30 |
David Kideckel
CHM | Chairman | - | 21-08-29 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-06 | 0.03 | 0.00% | 225,001 |
| 24-05-03 | 0.03 | 0.00% | 182,414 |
| 24-05-02 | 0.03 | 0.00% | 42,735 |
| 24-05-01 | 0.03 | +20.00% | 170,855 |
| 24-04-30 | 0.025 | -16.67% | 373,249 |
Delayed Quote Canadian Securities Exchange, May 06, 2024 at 10:35 am EDT
More quotes
PharmaDrug Inc. is a Canada-based specialty pharmaceutical company. The Company is focused on the research, development and commercialization of controlled-substances and natural medicines, such as psychedelics and previously approved drugs. The Companyâs subsidiary, Sairiyo Therapeutics (Sairiyo), is a biotech company that specializes in researching and reformulating established natural medicines. Sairiyo is engaged in the development of its patented reformulation of cepharanthine, a drug that has shown substantial third party validated potential for the treatment of infectious diseases (including Covid-19) and rare cancers. In clinical research, Cepharanthine exhibits multiple pharmacological effects, including anti-oxidative, anti-inflammatory, immuno-regulatory, anti-cancer, anti-viral and anti-parasitic properties. Sairiyo is also conducting research and development (R&D) in the psychedelics space for the treatment of non-neuropsychiatric conditions.
Sector
Pharmaceuticals
Calendar
2024-05-26
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -45.45% | 2.29M | |
| +15.21% | 69.5B | |
| -2.19% | 24.09B | |
| +8.13% | 8.2B | |
| -18.28% | 7.97B | |
| -0.98% | 7.84B | |
| +19.12% | 4.32B | |
| 0.00% | 4.19B | |
| -3.02% | 3.89B | |
| +23.97% | 3.62B |
- Stock Market
- Equities
- PHRX Stock